Akums Drugs and Pharmaceuticals Ltd – Q1 FY27 Financial Results

On 11 August 2026, Akums Drugs and Pharmaceuticals Ltd, identified as India’s largest contract development and manufacturing organization (CDMO), released its consolidated financial results for the quarter ended 30 June 2026, marking the first quarter of fiscal year 2027. The company recorded operating revenue of ₹1,167 crore, representing a 13.9% year‑on‑year increase over the ₹1,024 crore reported in Q1 FY26.

EBITDA for the quarter rose to ₹175 crore, a 35.4% increase from ₹129 crore in the comparable period last year, and the EBITDA margin improved to 15.0% from 12.6%. Net profit after tax (PAT) reached ₹101 crore, up 55.4% from ₹65 crore a year earlier, with the PAT margin expanding to 8.4% versus 6.2% previously.

The CDMO business remained the primary growth engine. CDMO‑related revenue climbed to ₹964 crore, up from ₹813 crore in Q1 FY26, while CDMO EBITDA increased 36.8% to ₹163 crore from ₹119 crore a year ago, driven by higher volumes and improved API pricing.

A detailed extract of the consolidated results shows:

  • Revenue: ₹1,167 crore (Q4 FY26: ₹1,158 crore; Q1 FY26: ₹1,024 crore)
  • Cost of goods sold: ₹645 crore (Q4 FY26: ₹660 crore; Q1 FY26: ₹582 crore)
  • Employee cost: ₹201 crore (Q4 FY26: ₹199 crore; Q1 FY26: ₹176 crore)
  • Other expenses: ₹145 crore (Q4 FY26: ₹147 crore; Q1 FY26: ₹137 crore)
  • EBITDA: ₹175 crore (Q4 FY26: ₹152 crore; Q1 FY26: ₹129 crore)
  • EBITDA margin: 15.0% (Q4 FY26: 13.1%; Q1 FY26: 12.6%)
  • PAT: ₹101 crore (Q4 FY26: ₹81 crore; Q1 FY26: ₹65 crore)
  • PAT margin: 8.4% (Q4 FY26: 6.8%; Q1 FY26: 6.2%)

In comments, Managing Director Sanjeev Jain described FY27 as having begun on a “strong and encouraging note,” emphasizing that the consistent CDMO performance reflects a healthy demand environment and client trust. Managing Director Sandeep Jain added that the firm remains focused on strengthening CDMO leadership, scaling high‑value capabilities, and driving operational excellence, noting a strong pipeline and prudent capital allocation that position the company for sustainable growth.

For further information, the press release lists the IR desk contacts at investors@akums.net and ankit.jain@akums.net. The release includes a disclaimer stating that it is provided under an arrangement with NRDPL and that PTI assumes no editorial responsibility.